Completed PHASE1 INTERVENTIONAL 1-arm NCT04921878

A Study of Mitoxantrone Hydrochloride Liposome Injection in Chinese Patients With Advanced Solid Tumors

Safety, Tolerability, Pharmacokinetics and Efficacy of Mitoxantrone Hydrochloride Liposome Injection in Chinese Patients With Advanced Solid Tumors: A Multicenter, Open-label, Phase I Dose-escalation and Dose-expansion Study

Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Conditions Advanced Solid Tumors

Interventions Mitoxantrone Hydrochloride Liposome injection

Updated 4 times since 2021 Last updated: Feb 7, 2024 Started: Jul 30, 2021 Primary completion: Apr 3, 2023 Completion: Apr 3, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Advanced Solid Tumors and is currently completed. CSPC ZhongQi Pharmaceutical Technology Co., Ltd. leads this study, which shows 4 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Mar 2024 — Jul 2024 [monthly]

Completed PHASE1

Status: Not Yet Recruiting → Completed
Sep 2021 — Mar 2024 [monthly]

Not Yet Recruiting PHASE1

First recorded

Jul 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Data source: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Baoding, China